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Abstract
Background: Fluoroquinolone resistant E. coli isolates, that are also resistant to other classes of antibiotics, is a
significant challenge to antibiotic treatment and infection control policies. In Central Greece a significant increase of
ciprofloxacin-resistant Escherichia coli has occurred during 2011, indicating the need for further analysis.
Methods: A total of 106 ciprofloxacin-resistant out of 505 E. coli isolates consecutively collected during an eight
months period in a tertiary Greek hospital of Central Greece were studied. Antimicrobial susceptibility patterns and
mechanisms of resistance to quinolones were assessed, whereas selected isolates were further characterized by
multilocus sequence typing and β-lactamase content.
Results: Sequence analysis of the quinolone-resistance determining region of the gyrA and parC genes has
revealed that 63% of the ciprofloxacin-resistant E. coli harbored a distinct amino acid substitution pattern (GyrA:S83L +
D87N; ParC:S80I + E84V), while 34% and 3% carried the patterns GyrA:S83L + D87N; ParC:S80I and GyrA:S83L + D87N;
ParC:S80I + E84G respectively. The aac (6’)-1b-cr plasmid-mediated quinolone resistance determinant was also detected;
none of the isolates was found to carry the qnrA, qnrB and qnrS.
Genotyping of a subset of 35 selected ciprofloxacin-resistant E. coli by multilocus sequence typing has revealed the
presence of nine sequence types; ST131 and ST410 were the most prevalent and were exclusively correlated with
hospital and health care associated infections, while strains belonging to STs 393, 361 and 162 were associated with
community acquired infections. The GyrA:S83L + D87N; ParC:S80I + E84V substitution pattern was found exclusively
among ST131 ciprofloxacin-resistant E. coli. Extended-spectrum β-lactamase-positive ST131 ciprofloxacin-resistant isolates
produced CTX-M-type enzymes; eight the CTX-M-15 and one the CTX-M-3 variant. CTX-M-1 like and KPC-2 enzymes
were detected in five and four ST410 ciprofloxacin-resistant E. coli isolates, respectively.
Conclusions: Our findings suggest that, ST131 and ST410 predominate in the ciprofloxacin resistant E. coli population.
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Background
Escherichia coli is among the major pathogens in both
community and hospital settings [1]. The prevalence of
multidrug-resistant E. coli, (i.e., E. coli isolates resistant to
more than three classes of antimicrobial agents) has been
increased worldwide in the past decades. The emergence
and worldwide dissemination of fluoroquinolone resistant
E. coli isolates, that are also resistant to newer β-lactams
due to the production of extended-spectrum β-lactamases
(ESBLs) particularly CTX-M-type enzymes, is a significant
challenge to antibiotic treatment and infection control
policies [1]. The application of multilocus sequence typing
(MLST) to isolates producing CTX-M-15 ESBL led to the
recognition of an internationally disseminated clone,
ST131, which is a virulent phylogroup B2, uropathogenic
E. coli lineage. ST131 E. coli is associated with resistance to
fluoroquinolones and aminoglycosides.
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Quinolones are widely used antimicrobials for the treat-
ment of bacterial infections [2]. Their wide use has
triggered increased bacterial resistance worldwide. Muta-
tions in gyrA and parC genes are the most common
mechanism involved in high-level quinolone resistance,
yet the spread of plasmid- mediated quinolone resistance
genes and efflux-pump mutants have also been described.
In Greece, according to the recent data of WHONET the
rate of ciprofloxacin resistant (CIP-R) E. coli varied from
hospital to hospital and ranged from 5.6 to 49.5%. In the
University Hospital of Larissa (UHL), that is the main ter-
tiary hospital of Central Greece and serves a region of
1,000,000 habitants, an increase of ciprofloxacin-resistant
E. coli from 16.3% in 2010 to 21% in 2011 was recorded.
The aim of this study was to assess the epidemiological
traits, mechanisms of resistance to fluoroquinolones,
phylogenetic relationship and co-existing mechanism of
resistance to newer β-lactams of CIP-R E. coli strains
isolated in our institution during 2011.
Methods
Bacterial isolates,susceptibility testing and clinical data
From May to December 2011, a total of 505 consecutive
E. coli isolates were recovered from clinical samples
taken as part of standard care of an equal number of
individual patients admitted to the University Hospital
of Larissa, Central Greece. Identification and antimicro-
bial susceptibility testing of bacterial isolates was firstly
performed by the Vitek-2 system (bioMérieux, Marcy
l’Étoile, France). The interpretive criteria of the European
Committee on Antimicrobial Susceptibility Testing were
used (http://eucast.org/clinical_breakpoints).
Determination of MICs to ciprofloxacin norfloxacin,
imipenem and meropenem was performed by the Etest
method (bioMérieux). The double disk synergy test
(DDST) was used to determine the ESBL production, as
described previously [3]. The modified Hodge test was
used for phenotypic detection of carbapenemase produc-
tion [3]. All E. coli, that were classified as resistant to
ciprofloxacin (MICs > =4 mg/L), were further analyzed
for the underlying mechanisms of quinolone resistance,
molecular typing and β-lactamase content.
The medical records of patients diagnosed with CIP-R
E. coli infection were reviewed regarding their current
and previous hospitalizations. Before obtaining the cli-
nical information of the patients, approval was received
by the Ethics Committee of the UHL, that is represented
by the Infection Control Committee (number of permis-
sion 1234). Infections developed 48 h after hospital
admission were characterized as UHL hospital-acquired
infections. Infections due to CIP-R E. coli diagnosed
within 48 h of hospital admission were characterized as
community acquired infections. Finally, infections in
patients who had been hospitalized in the preceding
6 months for more than 48 h in hospital facilities or
nursing homes such as infections in patients transmitted
to UHL from other hospitals were considered as health
care associated infections.
PCR and sequencing of the Quinolone Resistance-
Determining Region (QRDR) of the gyrA and parC genes
All Cip-R E. coli were screened for the presence of
mutations in the QRDR of the gyrA and parC genes.
After DNA extraction by using the Quick-gDNA TM
MiniPrep kit (ZYMO RESEARCH Corp., USA), the
QRDRs of both gyrA and parC genes were amplified by
polymerase chain reaction (PCR), as described previ-
ously [4] and the amplicons were sequenced on both
DNA strands using an ABI3730 DNA sequencer
(Applied Biosystems, Warrington, United Kingdom). For
each isolate, the sequences of the gyrA and parC gene
fragments were concatenated, maintaining the +1 rea-
ding frame, aligned and a neighbor-joining tree was
constructed from the aligned sequences using the
MEGA software [5].
Detection of plasmid-mediated quinolone resistance
genes qnrA, qnrB, qnrS and aac(6’)-Ib-cr variant
Primers and conditions for PCR amplification of the
qnrA, qnrB and qnrS genes, which encode three target-
protecting proteins and the aac(6’)-Ib-cr variant, which
encodes a bifunctional aninoglycoside- fluoroquinolone
modified enzyme, were used as described previously [6],
and the amplified PCR products obtained were sequenced
on both DNA strands as described previously.
Detection of beta-lactamases
Detection of the bla genes was performed by PCR
using a panel of specific primers for blaTEM-1, blaOXA-1,
blaSHV, blaCTX-M, blaCMY, blaVIM and blaKPC, as described
previously [7]. PCR products were purified by using the
PureLink™ PCR Purification Kit (Invitrogen, USA) kit and
sequenced. Nucleotide and deduced protein sequences
were identified by comparing the sequences of the data-
base of G. Jacoby and K. Bush (http://www.lahey.org/
Studies).
Molecular typing of isolates
Τhe major phylogenetic groups (A, B1, B2, D) were deter-
mined by PCR amplification of the three gene fragments of
the scheme (chuA, yjaA and TSPE4.C2). Phylogroups were
determined as described previously [8]. MLST was per-
formed by PCR amplification and sequencing of seven
housekeeping genes: adk (adenylate kinase), fumC (fumarate
hydratase), gyrB (DNA gyrase), icd (isocitrate/ isopropylma-
late dehydrogenase), mdh (malate dehydrogenase), purA
(adenylosuccinate dehydrogenase), recA (ATP/GTP binding
motif) by using primers and conditions as described at the
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MLST Databases at the ERI, University College Cork [9];
http://mlst.ucc.ie/mlstdbs/E.coli. Sequences were obtained
on both DNA strands, and alleles and STs were compared
with those assigned at the MLST website. Non overlapping
groups of related STs were identified using eBURST,
with the default setting for the definition of groups [10];
http://eburst.mlst.net.
Results
One hundred six out 505 (21%) E. coli isolates were
found to be resistant to quinolones. These isolates were
obtained from various clinical specimens; mainly from
urine (76 out of 106; 72%) and blood (12 out of 106;
11%), but also from bronchial secretions, cutaneous les-
sions and sputum. Among them, 30% (32 isolates) were
recovered from community acquired infections, 15% (16
isolates) from UHL hospital acquired infections and 55%
(58 isolates) from health care associated infections.
Among 106 CIP-R E. coli isolates, 57% showed
an ESBL phenotype, exhibiting resistance to penicillins,
expanded- spectrum cephalosporins and aztreonam,
while, 4.7% exhibited also resistance to at least one car-
bapenem, 72% were resistant to trimethoprim- sulfa-
methoxazole, 70% to tetracycline, 60% to tobramycin,
whereas, only 25% to gentamicin. Nineteen percent of
the CIP-R E. coli isolates exhibited concurrent resis-
tance to four other classes of antimicrobial agents,
58.5% to three classes, 13.2% to two classes and 3.8%
to one class; the remaining 5.5% showed resistance only
to quinolones.
Sequencing of the QRDR regions of the gyrA and parC
genes of CIP-R isolates has revealed three different
amino acid substitution patterns: GyrA:S83L + D87N;
ParC:S80I + E84V (n = 67, 63%), GyrA:S83L + D87N;
ParC:S80I (n = 36, 34%) and GyrA:S83L + D87N; ParC:
S80I + E84G (n = 3, 3%). All but one of the 67 CIP-R E.
coli isolates, that possessed the GyrA:S83L + D87N;
ParC:S80I + E84V pattern, showed identical nucleotide
sequences in the gyrA and parC, with the exception
showing only a synonymous nucleotide substitution in
the parC gene. In addition, the three isolates with the
GyrA:S83L + D87N; ParC:S80I + E84G pattern had
identical nucleotide sequences. On the contrary, the
nucleotide sequences of gyrA/ parC gene fragments of
the 36 CIP-R isolates with the GyrA:S83L + D87N;
ParC:S80I substitution pattern were found to be more
polymorphic.
Out of the 106 CIP-R coli isolates, 35 were selected for
further investigation including 21 with the pattern GyrA:
S83L + D87N; ParC:S80I + E84V, 13 with the pattern
GyrA:S83L + D87N; ParC:S80I, and one with the pattern
GyrA:S83L + D87N; ParC:S80I + E84G. The selection
was designed so as to include proportionally all the
variations in the amino and nucleotide acid substitution
patterns observed in the GyrA and ParC, the antimicro-
bial resistance patterns, the origin and the distribution
of the isolates over the study period (Table 1).
The 35 representative CIP-R E.coli isolates were dis-
tributed into phylogroups B2 (30 isolates), D (two iso-
lates), A (two isolates) and B1 (one isolate) [Table 1].
Genotyping by MLST has revealed the presence of nine
STs. ST131 (21 out 35 isolates), and ST410 (six out 35
isolates) were the most prevalent; ST44, ST90, ST162,
ST361, ST1140, ST2509 included one isolate, while,
ST393 included two isolates. According to clinical data,
all ST131 isolates were associated with UHL hospital
acquired infections and health care associated infections,
ST410 CIP-R E. coli were exclusively associated with
health care associated infections, while STs 393, 361 and
162 from community acquired infections. Strains that
belonged to ST90, 44, 1140 and 2509 were isolated from
patients with UHL hospital acquired infections.
Although, only three amino acid substitution patterns
in the GyrA/ParC were identified among the CIP-R E.
coli, we have sought to investigate any possible correla-
tions of the nucleotide polymorphisms and the STs of
the isolates. For this purpose, a neighbor-joining tree
was constructed from the concatenated sequences of the
gyrA/ parC gene fragments (Figure 1). The pattern
GyrA:S83L + D87N;ParC:S80I + E84V was associated
with ST131 strains possessing identical nucleotide
sequences, while, the GyrA:S83L + D87N; ParC:S80I was
found to various STs, including ST410. Except from one
isolate (ID 362), the rest isolates with this substitution
pattern differed in 12 polymorphic sites of the 643 bp
nucleotide sequence of the gyrA/parC fragments. The
third pattern, GyrA:S83L + D87N; ParC:S80I + E84G,
was associated with ST393 (ID 296). The isolate ID 362,
that belonged also to ST393, showed similarity in the
gyrA/ parC nucleotide sequences with the isolate ID 296
and they differed at only a single nucleotide site.
The presence of plasmid- mediated quinolone resist-
ance genes was also investigated in the 35 CIP-R E.coli
isolates (Table 1, Figure 1). The aac (6’)-1b-cr variant
was detected in 23 out of 35 CIP-R E.coli; of these 14
were ST131 and five ST410. The remaining four isolates
belonged to ST44, ST90 and ST162 and ST393. None
isolate was found to carry any of the qnrA, qnrB and
qnrS gene.
The β-lactamase content of the 35 Cip-R E. coli was
also determined (Table 1). ESBL- positive CIP-R isolates
were found to produce enzymes of the CTX-M-1
family (n = 15); CTX-M-15 (n = 12) and CTX-M-3
(n = 3). Among them, nine belonged to ST131, five to
ST410 and one to ST44 (Table 1). One out of the twelve
ESBL-negative ST131 was a VIM-1 producer. Three
ST410 CTX-M-producing strains co-produced the KPC-
2 carbapenemase.
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Table 1 Microbiological characteristics of the 35 representative CIP-R E. coli; phylogroups, MLST STs (clonal complexes;
Cplx), presence/absence of the aac (6’)-1b-cr variant and beta-lactamase content
Strain
ID
Isolation
date
Antimicrobial resistant pattern ESBL Phylogroup/ MLST
ST (CC)
aac
(6’)-Ib-cr
beta-lactamase content
GyrA:S83L + D87N/ ParC: S80I + E84V (n = 21)
347 13/6/2011 AM,AMC,CAZ,CTX,ATM,GM,NN,TE,SXT,CIP, NOR positive B2/ ST131 ( − ) CTX-M-15
161 27/5/2011 AM,AMC,CAZ,CTX,ATM, NN,TE,SXT,CIP NOR positive B2/ ST131 ( + ) CTX-M-15 + OXA-1
391 30/5/2011 AM,AMC,CAZ,CTX,ATM,GM,NN,TE,SXT,CIP,NOR positive B2/ ST131 ( + ) CTX-M-15 + OXA-1
392 9/6/2011 AM,AMC,CAZ,CTX,ATM,GM,NN,TE,SXT,CIP,NOR positive B2/ ST131 ( + ) CTX-M-15 + OXA-1
393 18/7/2011 AM,AMC,CAZ,CTX,ATM,GM,NN,TE,SXT,CIP,NOR positive B2/ ST131 ( + ) CTX-M-15 + OXA-1
399 2/8/2011 AM,AMC,CAZ,CTX,ATM,GM,NN,TE,SXT,CIP,NOR positive B2/ ST131 ( + ) CTX-M-15 + OXA-1
160 3/5/2011 AM,AMC,CAZ,CTX,ATM,SXT,CIP,NOR positive B2/ ST131 ( + ) CTXM-15 + TEM-1
505 4/9/2011 AM,AMC,CAZ,CTX,ATM,AN,GM,NN,SXT,CIP,NOR positive B2/ ST131 ( + ) CTX-M-15 + TEM-1 + OXA-1
397 4/8/2011 AM,AMC,CAZ,CTX,ATM,TE, SXT, CIP, NOR positive B2/ ST131 ( − ) CTX-M-3
270 1/5/2011 AM,AMC,NN,SXT,CIP,NOR negative B2/ ST131 ( + ) OXA-1
301 5/5/2011 AM, AMC,NN,TE,CIP,NOR negative B2/ ST131 ( + ) OXA-1
307 6/6/2011 AM,AMC, GM, NN, TE,CIP, NOR negative B2/ ST131 ( + ) OXA-1
252 1/5/2011 AM, SXT,CIP,NOR negative B2/ ST131 ( − ) TEM-1
206 16/5/2011 AM,AMC,GM,TE,SXT,CIP,NOR negative B2/ ST131 ( + ) TEM-1 + OXA-1
320 25/5/2011 AM,AMC,CIP,NOR negative B2/ ST131 ( + ) TEM-1 + OXA-1
346 3/6/2011 AM,AMC,AN,GM,NN,SXT,TE,CIP,NOR negative B2/ ST131 ( + ) TEM-1 + OXA-1
803 4/12/2011 AM,AMC,CAZ,CTX, IMP,MEM,CIP, NOR negative B2/ ST131 ( + ) VIM-1-like + TEM-1+ OXA-1
220 5/5/2011 TE, SXT,CIP,NOR negative B2/ ST131 ( − ) none
321 18/7/2011 CIP,NOR negative B2/ ST131 ( − ) none
354 1/7/2011 TE,CIP,NOR negative B2/ ST131 ( − ) none
355 15/8/2011 TE,SXT,CIP,NOR negative B2/ ST131 ( − ) none
GyrA:S83L + D87N/ ParC: S80I + E84G (n = 1)
296 6/8/2011 AM, TE, CIP, NOR negative D/ ST393 (ST31
Cplx)
( + ) TEM-1
Strain
ID
Isolation
date
Antimicrobial susceptibility pattern ESBL Phylogroup/MLST
ST (CC)
aac
(6’)-Ib-cr
beta-lactamase content
GyrA:S83L + D87N/ ParC: S80I (n = 13)
148 9/6/2011 AM,AMC,CAZ,CTX,ATM,IMP,MEM,NN,SXT,CIP,
NOR
positive B2/ ST410 ( + ) KPC-2 + CTXM-15 + TEM-1 +
OXA-1(ST23 Cplx)
182 17/5/2011 AM,AMC,CAZ,CTX,ATM,IMP,MEM,AN,NN,TE,CIP,
NOR
positive B2/ ST410 ( + ) KPC-2 + CTXM-3 + TEM-1+ OXA-
1(ST23 Cplx)
252 10/6/2011 AM,AMC,CAZ,CTX,ATM,IMP,MEM,NN,TE,CIP,NOR positive B2/ ST410 ( + ) KPC-2 + CTXM-3 + TEM-1 + OXA-
1(ST23 Cplx)
648 31/12/2011 AM,AMC,CAZ,CTX,IMP,MEM,NN,TE,CIP,NOR negative B2/ ST410 ( − ) KPC-2 + TEM-1
(ST23 Cplx)
132 24/5/2011 AM,AMC,CAZ,CTX,ATM,AN,NN,TE,SXT,CIP,NOR positive B2/ ST410 ( + ) CTXM-15 + TEM-1 + OXA-1
(ST23 Cplx)
281 15/8/2011 AM,AMC,CAZ,CTX,ATM,AN,GM,NN,TE,SXT,CIP,
NOR
positive B2/ ST410 ( + ) CTXM-15 + OXA-1
(ST23 Cplx)
384 30/11/2011 AM,AMC,CAZ,CTX,ATM,AN,TE,SXT,CIP,NOR positive B2/ ST44 ( + ) CTXM-15
(ST10 Cplx)
383 22/9/2011 AM,TE,SXT,CIP,NOR negative A/ ST90 ( + ) TEM-1
(ST23 Cplx)
259 14/7/2011 AM,TE,SXT,CIP,NOR negative B1/ ST162 ( + ) TEM-1
(ST469 Cplx)
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Discussion
During an eight months period of 2011, CIP-R E. coli
accounted for 21% of the total E. coli isolates recovered
from various clinical specimens from outpatients and
inpatients of the UHL. The majority of the CIP-R E. coli
isolates were multidrug-resistant, posing a challenge for
therapeutic options. Only 5.5% were resistant to fluoro-
quinolones, but susceptible to various antimicrobial
classes. The latter strains were recovered from both
community and hospital acquired infections.
The majority of CIP-R E. coli belonged to ST131 and
ST410, which were recovered from hospital and health
care associated infections, whereas other studies have
shown that such strains were disseminated in the
community [11-16]. We have also shown previously that
ST410 was linked with an outbreak of KPC- producing
E. coli in a long-term care facility unit of Thessalia
[17]; this clone, apart from carbapenemase producers,
includes also isolates with CTX-M-15, as it was firstly
reported in Spain [16]. All ST131 and ST410 CIP-R E.
coli belonged to the virulent phylogroup B2, which is
associated epidemiologically and experimentally with
extraintestinal virulence [12,18]. The remaining isolates,
that were isolated in a sporadic fashion in our study,
were distributed equally to various STs, which have been
previously reported among Cip-R E. coli isolates, and
originated from community and hospital acquired infec-
tions [15].
Figure 1 Neighbor- joining tree of the 35 representative CIP-R E. coli; for each isolate, the GyrA/ParC amino acid substitution pattern,
the presence/absence of the aac (6’)-1b-cr variant and the MLST ST is indicated.
Table 1 Microbiological characteristics of the 35 representative CIP-R E. coli; phylogroups, MLST STs (clonal complexes;
Cplx), presence/absence of the aac (6’)-1b-cr variant and beta-lactamase content (Continued)
328 10/9/2011 AM,SXT,CIP,NOR negative B2/ ST361 ( − ) TEM-1
362 21/10/2011 AM,TE,SXT,CIP,NOR negative D/ ST393 ( − ) TEM-1
(ST31 Cplx)
129 25/5/2011 AM,TE,SXT,CIP,NOR negative B2/ ST1140 ( − ) TEM-1
327 9/6/2011 CIP, NOR negative A/ ST2509 ( − ) none
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In Greece, there are few studies on the mechanisms of
resistance to fluoroquinolones [19-21], but to our know-
ledge this is the first report on the association of gyrA
and parC mutations and the phylogenetic lineages of
ciprofloxacin-resistant E. coli in Greece. According to
our results, ST131 and ST410 carried specific patterns
of GyrA/ParC amino substitutions. In more details,
ST131 Cip-R E. coli in our hospital possessed the same
amino acid substitution pattern GyrA:S83L + D87N;
ParC:S80I + E84V, which has been previously identified
among ST131 CIP-R E. coli isolated from humans and
companion animals in the United States, United King-
dom, Australia and Korea [13-15]. On the other hand,
the six ST 410 E. coli of our study carried the GyrA:
S83L + D87N; ParC:S80I pattern, which has been identi-
fied in previous studies [22,23]. Nevertheless, the
sequence types of the latter strains have not been
determined.
The presence of plasmid-mediated resistance genes
(qnrA, qnrB and qnrS) has also been reported in previ-
ous studies in Greece [19-21], but these genes were not
detected in our collection of CIP-R E. coli isolates. On
the other hand, the aac (6’)-1b-cr variant was detected
mainly in strains belonging to both ST131 and ST410, a
finding that was also previously described [13,16].
Since isolates possessing the GyrA:S83L + D87N;
ParC:S80I + E84V comprised a high percentage (67%)
among CIP-R E. coli, and the representative isolates of
this group have been assigned to ST131, we assume that
the increase of fluoroquinolone-resistance during 2011
can be attributed to the dissemination of ST131 strains.
The source and the time of importation of these isolates
are unknown. As mentioned previously, since ST131
was first described in 2008 [24], it has disseminated
worldwide [11-15,23-26]. Several factors such as host-to-
host or foodborne transmission or environmental con-
tamination have been suggested to contribute in their
dissemination; reservoirs of ST131 have been identified
in food and water sources, in nursing home residents,
companion animals and food sources [27-29].
Central Greece is a rural area, where fluoroquinolones
are widely used in veterinary and poultry, but no data
exist about the incidence of resistant E. coli of animal
source. It would be interesting to investigate the
mechanisms of resistance and genetic relatedness of
such strains in future studies. These studies would eluci-
date the relationships between STs of isolates recovered
from human and animals and the roots of transmission.
Conclusions
In the present study we have characterized the mecha-
nisms of resistance and explored the genetic relatedness
of CIP-R E. coli recovered from community, hospital
and health care associated infections in a tertiary care
hospital in Central Greece. Our findings suggest that
ST131 and ST410 predominate in the CIP-R E. coli
population in our institution. The increase of resistance
to fluoroquinolones observed during 2011 is attributed
mainly to the wide dissemination of ST131 CIP-R.
E. coli.
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